NCT05976230

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,125 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, multicenter, observational study to evaluate the safety and efficacy of Entresto Tablets during the first 52 weeks of treatment in Japanese patients with hypertension.

Detailed description

This study is a special drug use surveillance to collect information on the safety specifications under the actual clinical practice of Entresto Tablets in patients with hypertension in Japan to confirm the occurrence and timing of onset of events related to the safety specifications and investigate their risk factors.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Entresto	There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.

Timeline

• Start date: 2023-09-04
• Primary completion: 2025-05-29
• Completion: 2025-05-29
• First posted: 2023-08-04
• Last updated: 2025-07-03

Locations

117 sites across 1 country: Japan